← Back to Clinical Trials
Recruiting NCT07683650

NCT07683650 Hyaluronic Acid and I-PRF Mixture for TMJ Disc Displacement Management

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07683650
Status Recruiting
Phase —
Sponsor Mansoura University
Condition TMJ Disc Displacement With Reduction
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2026-01-06
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
18 joints that receive arthrocentesis using 100 ml of ringer lactate solutionArthrocentesis followed by hyaluronic acid injectionArthrocentesis followed by injection of hyaluronic acid and betamethasone mixture

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 72 participants in total. It began in 2026-01-06 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to evaluate the efficacy of hyaluronic acid and I-PRF mixture for intra-articular injection following arthrocentesis in the management of TMJ reducible disc displacement.

Eligibility Criteria

Inclusion Criteria: 1. Age: 18 - 45 years. 2. Patients with disc displacement with reduction in any of the TMJs. 3. arthralgia. 4. Limited unassisted mouth opening. 5. Co-operative patients. Exclusion Criteria: 1. Patients with previous history of TMJ minimally invasive interventions. 2. Patients with autoimmune or connective tissue diseases affecting the joints. 3. Patients with neurological disorders. 4. Patients with a history of condylar fractures or ankylosis. 5. Patients with psychological problems. 6. Patients receiving non-steroidal anti-inflammatory drugs within 48 hours preoperatively, or systemic use of corticosteroids within 2 weeks. 7. Patients on anticoagulants, suffering from platelet function disorders or fibrinogen deficiency. 8. Patients with moderate to severe myogenic pain.

Contact & Investigator

Central Contact

Nada Hamed

✉ hamednada99@mans.edu.eg

📞 00201119659235

Principal Investigator

Nada Hamed

PRINCIPAL INVESTIGATOR

Faculty of Dentistry Mansoura University

Frequently Asked Questions

Who can join the NCT07683650 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying TMJ Disc Displacement With Reduction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07683650 currently recruiting?

Yes, NCT07683650 is actively recruiting participants. Contact the research team at hamednada99@mans.edu.eg for enrollment information.

Where is the NCT07683650 trial being conducted?

This trial is being conducted at Al Mansurah, Egypt.

Who is sponsoring the NCT07683650 clinical trial?

NCT07683650 is sponsored by Mansoura University. The principal investigator is Nada Hamed at Faculty of Dentistry Mansoura University. The trial plans to enroll 72 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology